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Background: A phase I–II multicenter trial was conducted to define the maximal tolerated dose
and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and
5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC).
Patients and methods: CRC patients not pretreated with palliative chemotherapy, with performance
status <_1 and adequate haematological, kidney and liver function, were eligible. Treatment consisted
in weekly 24-h infusion 5-FU (2300 mg/m2)/LV (30 mg) and alternating OHP (70–85 mg/m2, days 1
and 15) and CPT-11 (80–140 mg/m2, days 8 and 22) repeated every 5 weeks. OHP and CPT-11
were escalated in cohorts of three to six patients.
Results: Thirty patients received a median of five cycles. Dose-limiting toxicity occurred at dose
level 3, and the recommended dose was OHP 70 mg/m2, CPT-11 100 mg/m2, LV 30 mg and 5-FU
2300 mg/m2/24 h. Grade >_3 toxicities were diarrhea 23%, neutropenia 20%, fatigue 7%, and neuro-
logic 7%. Two febrile neutropenia episodes (one fatal) were recorded. Among 28 patients with mea-
surable disease (90%), we observed two complete and 20 partial responses; overall RR was 78%
(95% CI, 59% to 92%). Median time to progression and overall survival were 9.5 and 25.4 months,
respectively. Seven patients underwent liver metastases resection.
Conclusion: OCFL is an overall well tolerated regimen with very high efficacy, which makes it
most suitable for tumour control before surgery of metastatic disease.
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Introduction
Colorectal cancer (CRC) is the second cause of cancer death
in Western countries. About 50% of all patients with CRC
develop distant metastatic disease and will be candidates for
palliative chemotherapy. Up to the mid-1990s, systemic
therapy of CRC was essentially based on 5-fluorouracil (FU)
with response rates of 15%–25% and overall median survival
times rarely exceeding 10–13 months in metastatic disease [1,
2]. The development of CPT-11, a topoisomerase I inhibitor,
and of oxaliplatin (OHP), a new platin derivative, has dramati-
cally changed the prospect of systemic therapy in this disease.
The combination of 5-FU with either CPT-11 or oxaliplatin
has allowed an increase in response rates to over 50% in first-
line therapy, and 20% when used as second-line chemotherapy
[3–9]. In addition, the consecutive prescription of CPT-11
and OHP-containing regimens to metastatic CRC patients has
also increased life expectancy of patients with metastatic
colorectal cancer to over 20 months from only 9–12 months
previously [10].
In patients with liver metastases only, these high response
rates have allowed for resection of initially inoperable disease
[11]. In order to increase the response rate further and to con-
sider subsequent curative intent resection of liver metastases,
we aimed to develop a five-drug combination regimen using
all known active agents concomitantly and alternately. In a
disease-specific phase I/II trial design we administered weekly
infusional 5-FU/leucovorin (LV) in combination with either
CPT-11 or oxaliplatin.
Patients and methods
Patient selection
Patients with measurable or evaluable (e.g. increased carcinoembryonic
antigen) disease from histologically proven colorectal adenocarcinoma
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were eligible. No previous chemotherapy for metastatic disease was
allowed. Patients who had received prior adjuvant 5-FU/ LV chemother-
apy after resection of the primary tumour were eligible, provided the adju-
vant chemotherapy was completed more than 6 months before relapse.
Other inclusion criteria were a World Health Organisation (WHO) per-
formance status of 0–1, age between 18 and 70 years, adequate blood
counts (leucocytes >_ 4 109/l and platelets <_100 109/l), adequate renal
and liver functions creatinin 1.25 upper normal limit (UNL), bilirubin
1.25UNL, AST and ALT <_ 3UNL (in cases of liver metastasis biliru-
bin 1.5 UNL, AST and ALT <_ 5UNL). Patients suffering from chronic
grade >_2 diarrhoea, other serious illness and past or concurrent history of
cancer, except non-melanoma skin cancer, and in situ cervical cancer
were excluded.
Study design and treatment scheme
The treatment consisted of weekly administration of a 24-h infusion of
5-FU (2300 mg/m2), LV 30 mg i.v. on days 1, 8, 15 and 22, escalating
doses of OHP (70–85 mg/m2) on day 1 and 15, and CPT (80–100 mg/m2)
on days 8 and 22, as shown in Figure 1. Treatment cycles were repeated
every 5 weeks. Dose levels and escalation scheme are presented in
Table 1. A minimum of three patients were to be treated at the same dose
level. If no dose limiting toxicity (DLT)—defined as grade 4 haematologi-
cal toxicity with fever (single oral temperature >38.5 8C, or three
elevations to 38 8C during a 24-h period) and/or grade 3 toxicity of any
other kind apart from alopecia—occurred during the first cycle of treat-
ment, the next three patients were treated at the next higher dose level. If
one DLT occurred in cycle 1, three additional patients had to be treated at
the same dose level. If two or more DLTs occurred at a given dose level,
this would define the maximally tolerated dose (MTD) and the dose just
below would be considered the recommended dose for future phase II
trials.
Another six patients were to be treated at the recommended dose, in
order to ensure the safety of the regimen.
Administration of treatment
Patients were treated through an implantable central venous device in an
outpatient setting. OHP was given as a 2-h i.v. infusion on days 1 and 15,
and CPT-11 as a 30-min i.v. infusion on days 8 and 22, always followed
by 5-FU as a continuous infusion over 24 h. Patients received standard
antiemetic premedication, including 5-hydroxytryptamine 3 receptor
antagonists and steroids. In order to prevent a cholinergic syndrome, on
the days of CPT-11 administration, patients received atropin 0.25 mg s.c.
Patients were instructed to manage late diarrhoea by loperamide and nau-
sea and vomiting with metoclopramide. No granulocyte colony stimulating
factors were to be used except for febrile neutropenia.
Toxicity assessment, dose reductions and evaluation
of response
Physical examination and blood cell counts were performed weekly and
biochemistry at the beginning of each cycle. Adverse reactions were
graded according to the WHO common toxicity criteria with specific
scales to assess plantar–palmar syndrome and OHP-related neuropathy. In
case of >_grade 3 neutropenia or thrombocytopenia or for any grade 3–4
non-haematological toxicity, doses of all cytotoxic agents were reduced
by 25% for the subsequent courses. OHP was to be discontinued if periph-
eral neuropathy grade 3 or other severe neurotoxicity were observed. A
maximum of a 1-week delay (14 days between two treatments) was
allowed for severe toxicity. Responses were assessed according to the
WHO criteria at the end of every two cycles of treatment. The main goal
of the trial was to determine the MTD of the regimen under investigation.
Statistical analysis was descriptive and survival was calculated according
to the Kaplan–Meier method.
The trial was approved by the ethics review boards of all participating
institutions. All patients gave informed written consent.
Results
Patient characteristics
From December 1999 to June 2001, 31 patients were enrolled
in the study. One patient presented cardiac arrhythmia just
after inclusion and never started study treatment. He was
therefore excluded from the analysis. All the remaining 30
patients received at least two cycles of treatment and were
fully assessable. The baseline patients’ characteristics are sum-
marised in Table 2. There were 24 males and six females;
Figure 1. Treatment scheme
Table 1. Dose escalation scheme
Level OXA (mg/m2) CPT-11 (mg/m2) LCV (mg) 5-FU (g/m2)
1 70 80 30 2.3
2 70 100 30 2.3
3 85 100 30 2.3
4 85 120 30 2.3
Table 2. Characteristics of patients
No. of patients 30
Age, years [median (range)] 58 (31–70)
Sex (male/female) 24/6
Performance status (0/1) 23/7
Bidimensionally measurable disease 28/30
Primary tumour:
Colon 8
Sigmoid-rectum 5
Rectum 17
Metastasis sites:
Liver 15
Lung 6
Lymph nodes 2
Liver and lung 4
Lymph nodes, liver and lung 1
Previous surgery of primary tumor 15/30
Prior adjuvant therapy by 5FU/LCV 6/30
763
the median age was 58 years. Fifteen patients had had their
primary tumour resected and six patients had received prior
5-FU/LV adjuvant chemotherapy. Twenty-eight patients had
bidimensionally measurable disease and two patients had
evaluable disease only.
Dose escalation findings
The number of patients entered in each dose level and the
type of DLTs encountered are summarised in Table 3.
Twelve patients were enrolled at dose level 1 (OHP
70 mg/m2 and CPT-11 80 mg/m2). Among the first six patients
enrolled, we observed the occurrence of one episode of febrile
neutropenia and grade 3 diarrhoea in the same patient during
the first cycle of treatment (one DLT), necessitating an
additional three patients to be treated at this dose level. Sub-
sequently, another patient developed grade 4 neutropenia and
an ileus due to peritoneal carcinomatosis during cycle 2. It
was therefore decided to confirm the safety in another six
patients before allowing dose escalation. No further DLT was
observed.
At dose level 2 (OHP 70 mg/m2 and CPT-11 100 mg/m2),
six patients were initially entered. One patient developed non-
haematological DLT consisting of grade 3 nausea/vomiting
and grade 3 fatigue. After determining this dose level as the
recommended dose, an additional five patients were treated
without severe toxicity.
At dose level 3 (OHP 85 mg and CPT-11 100 mg/m2) two
out of six patients developed grade 3 diarrhoea. Thus, this
dose level was considered to be the MTD and dose level 2 the
recommended phase II dose.
Because of delayed reporting of the second DLT in level 3,
one patient started therapy at dose level 4 (OHP 85 mg/m2 and
CPT-11 120 mg/m2). No significant toxicity was observed
during four cycles at this dose level before undergoing cura-
tive resection of liver metastasis.
Toxicity assessment
The toxicity analysis is based on 30 patients and 135 cycles of
treatment. Overall this regimen was well tolerated and a
median of 4 cycles/patient was administered (range 2–9).
Treatment delays were required in 12% of cycles (16
patients). Twelve patients completed 6 or more cycles of treat-
ment, and five patients with responding tumours discontinued
therapy early in order to undergo surgery and resection of
their liver metastases. Reasons for treatment discontinuation
were tumour progression in five patients (17%), toxicity also
in five patients [grade 3 neurotoxicity after 4 cycles (one
patient), grade 3 diarrhoea after 2 cycles (one patient), ileus or
pulmonary embolism after cycle 2 (two patients), fatal fungal
septicaemia at the end of the second cycle (one patient)], and
personal treatment unrelated reasons in three patients.
Details on the treatment-related worst toxicity are reported
in Tables 4 and 5. Grade 3/4 toxicity was infrequent, grade
3/4 diarrhoea occurred in seven patients (23%) and 8% of all
treatment cycles. Grade 3/4 neutropenia was observed in 20%
of patients and 6% of cycles, but only two febrile episodes,
although one fatal fungal infection.
Treatment efficacy
Twenty-eight patients had bidimensionnally measurable
disease (Table 6). Two complete (CR) and 20 partial
responses (PR) were recorded, for a response rate of 78%
(22/28 patients, 95% CI 59% to 92%). Five patients had stable
disease during at least 4 cycles of treatment and one patient
progressed after 2 cycles. The median time to progression was
9.5 months, and the median overall survival was 25.4 months
Table 3. Dose limiting toxicity according to dose level
Dose levels No. of
patients
DLTs Cycle number
(median)
1 12 Diarrhoea + febrile
neutropenia grade 3 (1)
5
2 6 Nausea-vomiting
grade 3 + fatigue grade 3 (1)
6
3 6 Diarrhoea grade 3 (2) 4
4 1 None NA
Table 4. Worst toxicity in percentage of patients (patient number = 30)
Toxicity grade 1 2 3 4
Nausea/vomiting (%) 43 43 3 0
Diarrhoea (%) 30 17 20 3
Mucositis (%) 13 3 0 0
Fatigue (%) 57 27 7 0
Neurological according to OHP scale (%) 60 7 7 NA
Plantar–palmar syndrome (%) 3 0 0 NA
Other neurological/dizziness (%) 13 0 0 0
Alopecia (%) 13 0 0 0
Neutropenia (%) 23 20 17 3
Febrile neutropenia (%) NA NA 3 3
Thrombopenia (%) 53 7 0 0
Table 5. Toxicity in percentage of cycles (number of cycles = 135)
Toxicity grade 1 2 3 4
Nausea/vomiting (%) 32 13 1 0
Diarrhea (%) 26 7 7 1
Mucositis (%) 4 1 0 0
Fatigue (%) 36 11 1 0
Neurological according to OHP scale (%) 39 4 1 NA
Plantar–palmar syndrome (%) 1 0 0 NA
Other neurological/dizziness (%) 4 0 0 0
Neutropenia (%) 18 7 5 1
Febrile neutropenia (%) NA NA 1 1
Thrombopenia (%) 41 1 0 0
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(Figure 2). At the time of the present analysis, 19 patients
have died.
Discussion
This study shows that oxaliplatin, irinotecan and 5-FU/LV
(OCFL) can be safely combined in a single regimen. Alternat-
ing oxaliplatin and irinotecan within the same treatment regi-
men allows the use of non-cross-resistant chemotherapy
agents while avoiding overlapping toxicity and potential, at
the time of study conception, unknown pharmacological inter-
actions [12]. Compared with other triplet regimens, where all
the drugs are administered on the same day, alternating OCFL
is less haematoxic. Grade 3/4 neutropenia in 20% patients
with 7% febrile neutropenia, as reported in our study, com-
pares favourably with the 38% and 86% reported by others
[12, 13] with 14% febrile neutropenia. Diarrhoea was our
main non-haematological toxicity with 23% of the patients
experiencing grade 3/4 diarrhoea during the course of their
treatment. Five of these patients resumed therapy after a 25%
dose reduction of the 5-FU dose and no further severe diar-
rhoea occurred. Recent publications suggest the use of 5-FU
at a slightly lower dose, i.e. 2 g/m2/24 h weekly in association
with LV and irinotecan [14, 15]. Similarly, our experience
with this regimen after closure of this trial suggests a signifi-
cant reduction in severe diarrhoea with the lower dose of 5-
FU. Recently, Cals et al. [16] reported on their experience of
escalating doses of a similar regimen of weekly 5-FU and
alternating CPT11 and oxaliplatin. Their regimen did not con-
tain LV and the recommended phase II doses are slightly
higher than in our OCFL regimen.
Our trial only included patients who had not received prior
chemotherapy for metastatic disease. This allowed us to assess
the activity of this regimen. The observed response rate of
78% is amongst the highest response rates ever reported for
metastatic colorectal cancer [12, 13, 17, 18] and almost identi-
cal to the reported 71% by Falcone et al. [12] with the conco-
mitant biweekly association of 5-FU/LV, CPT11 and
oxaliplatin. Similarly, the time to progression and overall sur-
vival are also comparable between the two studies (9.5 and
25.4 months, respectively, in our study compared with 10.5
and 26.5 months).
High response rates and a short time to response make
these triplet regimens especially suited for patients planning
surgical resection of metastases, in particular liver metastases
initially considered unresectable. In our trial, seven patients
(23%) with a diagnosis of unresectable liver metastases under-
went curative-intent resection of the residual disease after an
initial response to chemotherapy. Similarly, in the trial
reported by Falcone, 25% of patients underwent subsequent
surgery.
The occurrence of severe hepatic sinusoidal obstruction
associated with oxaliplatin-based chemotherapy has recently
been reported in patients with metastatic colorectal cancer
[19]. Liver surgery is more difficult and prone to compli-
cations in this situation. The dose of oxaliplatin per cycle
(140 mg/m2) in our OCFL regimen is lower than in other tri-
plet regimens and thus less likely to induce such liver lesions.
In conclusion, OCFL is an efficient and, overall, usually
well-tolerated outpatient regimen. It is associated with high
response rates and most suitable for tumour control before sur-
gical treatment of metastatic disease.
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